17
Participants
Start Date
March 22, 2021
Primary Completion Date
October 12, 2021
Study Completion Date
October 12, 2021
Low dose ORTD-1
Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
Low dose vehicle control
Once weekly subcutaneous injection of vehicle at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
High dose ORTD-1
Two subcutaneous injections of ORTD-1 at two injection sites once weekly; 0.90 mL of ORTD-1 per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
High dose vehicle control
Two subcutaneous injections of vehicle at two injection sites once weekly; 0.90 mL of vehicle per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
Advanced Pharma CR, LLC, Miami
Keck School of Medicine of USC Division of Rheumatology, Los Angeles
Orange County Research Center, Tustin
Lead Sponsor
Oryn Therapeutics, LLC
INDUSTRY